Patrick Donnelly
Stock Analyst at Citigroup
(3.49)
# 869
Out of 5,182 analysts
349
Total ratings
47.92%
Success rate
4.93%
Average return
Main Sectors:
Stocks Rated by Patrick Donnelly
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TXG 10x Genomics | Maintains: Neutral | $18 → $24 | $22.08 | +8.70% | 14 | Apr 7, 2026 | |
| BIO Bio-Rad Laboratories | Downgrades: Neutral | $375 → $300 | $287.84 | +4.22% | 18 | Apr 7, 2026 | |
| BIO.B Bio-Rad Laboratories | Downgrades: Neutral | $375 → $300 | $299.45 | +0.18% | 18 | Apr 7, 2026 | |
| MDLN Medline | Reinstates: Buy | $60 | $44.76 | +34.05% | 3 | Mar 11, 2026 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $200 → $120 | $102.17 | +17.45% | 11 | Mar 11, 2026 | |
| STVN Stevanato Group | Maintains: Buy | $32 → $26 | $16.18 | +60.69% | 5 | Mar 5, 2026 | |
| SHC Sotera Health Company | Maintains: Buy | $21 → $23 | $15.58 | +47.63% | 4 | Feb 24, 2026 | |
| GH Guardant Health | Maintains: Buy | $135 → $150 | $88.91 | +68.71% | 12 | Feb 20, 2026 | |
| BRKR Bruker | Maintains: Neutral | $53 → $40 | $36.55 | +9.44% | 19 | Feb 13, 2026 | |
| QDEL QuidelOrtho | Maintains: Neutral | $23 → $30 | $11.59 | +158.84% | 7 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $7.90 | +39.24% | 9 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $190 → $215 | $196.27 | +9.54% | 12 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $55 | $38.41 | +43.19% | 15 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $230 → $200 | $162.28 | +23.24% | 14 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $70 → $80 | $54.19 | +47.64% | 13 | Feb 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $660 → $685 | $469.71 | +45.83% | 22 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $265 | $169.80 | +56.07% | 22 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $300 | $203.75 | +47.24% | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $21 | $9.80 | +114.29% | 5 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $165 → $185 | $115.55 | +60.10% | 27 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,600 → $1,700 | $1,282.45 | +32.56% | 15 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $42 | $20.20 | +107.92% | 2 | Aug 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $85 → $80 | $127.88 | -37.44% | 17 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $285 → $265 | $177.25 | +49.51% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $135 → $145 | $86.77 | +67.11% | 1 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $265 → $300 | $309.87 | -3.19% | 24 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $9 | $3.00 | +200.00% | 6 | Dec 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.75 → $2.75 | $2.01 | +36.82% | 4 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $250 → $260 | $263.80 | -1.44% | 11 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $6.10 | -1.64% | 4 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $28 → $32 | $4.78 | +569.46% | 2 | Nov 30, 2018 |
10x Genomics
Apr 7, 2026
Maintains: Neutral
Price Target: $18 → $24
Current: $22.08
Upside: +8.70%
Bio-Rad Laboratories
Apr 7, 2026
Downgrades: Neutral
Price Target: $375 → $300
Current: $287.84
Upside: +4.22%
Bio-Rad Laboratories
Apr 7, 2026
Downgrades: Neutral
Price Target: $375 → $300
Current: $299.45
Upside: +0.18%
Medline
Mar 11, 2026
Reinstates: Buy
Price Target: $60
Current: $44.76
Upside: +34.05%
ICON Public Limited Company
Mar 11, 2026
Maintains: Neutral
Price Target: $200 → $120
Current: $102.17
Upside: +17.45%
Stevanato Group
Mar 5, 2026
Maintains: Buy
Price Target: $32 → $26
Current: $16.18
Upside: +60.69%
Sotera Health Company
Feb 24, 2026
Maintains: Buy
Price Target: $21 → $23
Current: $15.58
Upside: +47.63%
Guardant Health
Feb 20, 2026
Maintains: Buy
Price Target: $135 → $150
Current: $88.91
Upside: +68.71%
Bruker
Feb 13, 2026
Maintains: Neutral
Price Target: $53 → $40
Current: $36.55
Upside: +9.44%
QuidelOrtho
Feb 12, 2026
Maintains: Neutral
Price Target: $23 → $30
Current: $11.59
Upside: +158.84%
Feb 12, 2026
Maintains: Neutral
Price Target: $13 → $11
Current: $7.90
Upside: +39.24%
Feb 10, 2026
Maintains: Neutral
Price Target: $190 → $215
Current: $196.27
Upside: +9.54%
Feb 6, 2026
Maintains: Neutral
Price Target: $55 → $55
Current: $38.41
Upside: +43.19%
Feb 6, 2026
Maintains: Neutral
Price Target: $230 → $200
Current: $162.28
Upside: +23.24%
Feb 5, 2026
Maintains: Buy
Price Target: $70 → $80
Current: $54.19
Upside: +47.64%
Jan 30, 2026
Maintains: Buy
Price Target: $660 → $685
Current: $469.71
Upside: +45.83%
Jan 16, 2026
Maintains: Buy
Price Target: $200 → $265
Current: $169.80
Upside: +56.07%
Jan 7, 2026
Initiates: Buy
Price Target: $300
Current: $203.75
Upside: +47.24%
Dec 11, 2025
Upgrades: Buy
Price Target: $12 → $21
Current: $9.80
Upside: +114.29%
Nov 25, 2025
Maintains: Buy
Price Target: $165 → $185
Current: $115.55
Upside: +60.10%
Nov 10, 2025
Maintains: Buy
Price Target: $1,600 → $1,700
Current: $1,282.45
Upside: +32.56%
Aug 13, 2025
Maintains: Buy
Price Target: $34 → $42
Current: $20.20
Upside: +107.92%
Jul 9, 2025
Downgrades: Sell
Price Target: $85 → $80
Current: $127.88
Upside: -37.44%
Jan 30, 2025
Maintains: Buy
Price Target: $285 → $265
Current: $177.25
Upside: +49.51%
Jul 30, 2024
Maintains: Buy
Price Target: $135 → $145
Current: $86.77
Upside: +67.11%
Dec 11, 2023
Maintains: Neutral
Price Target: $265 → $300
Current: $309.87
Upside: -3.19%
Dec 11, 2023
Maintains: Buy
Price Target: $7 → $9
Current: $3.00
Upside: +200.00%
Aug 10, 2023
Maintains: Neutral
Price Target: $3.75 → $2.75
Current: $2.01
Upside: +36.82%
Feb 17, 2023
Maintains: Neutral
Price Target: $250 → $260
Current: $263.80
Upside: -1.44%
Nov 3, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $6.10
Upside: -1.64%
Nov 30, 2018
Upgrades: Neutral
Price Target: $28 → $32
Current: $4.78
Upside: +569.46%